Study of Effect of supplementation of Zingiber Officinale on pharmacokinetic profile of Sitagliptin phosphate on Streptozotocin induced type II DM Rat Model

  • Swati Dhande Bharati Vidyapeeth's College of Pharmacy
  • Aruhana Patil Bharati Vidyapeeth's College of Pharmacy
  • Lilasrao Kadam Bharati Vidyapeeth's College of Pharmacy
Keywords: Diabetes Mellitus, metabolic endocrine disorder


Diabetes Mellitus (DM) is a metabolic endocrine disorder. It is one of the most rapidly growing diseases worldwide. Various pharmacotherapies have been practiced in the cure and management of DM. The existing conventional therapies aims at reducing hyperglycemia and achieving better glycemic control over the time, but fail to combat the other risk factors associated with the disease. The newer approaches are targeting to combat the risk factors and reduce the progression of disease. The newer approaches includes regenerational therapies, use of herbal and natural supplements, use of antioxidants and use combinations of conventional therapies with above mentioned therapies. Though these combinations have been found to be promising in the management of DM, the risk of pharmacological interactions cannot be overlooked. The present study was conducted to evaluate the pharmacokinetic interaction between DPP-IV inhibitor sitagliptin and a nutraceutical Z. officinale. STZ (Streptozotocin) and HFD (High Fat Diet) induced Type II DM rat model was used and the possible interaction was determined. The evaluation was done on validated HPTLC bioanalytical method. The present combination of sitagliptin and ginger did not affect the pharmacokinetic profile of sitagliptin.

Author Biographies

Swati Dhande, Bharati Vidyapeeth's College of Pharmacy

Bharati Vidyapeeth's College of Pharmacy,
Belapur, Navi Mumbai, India

Aruhana Patil, Bharati Vidyapeeth's College of Pharmacy

Bharati Vidyapeeth's College of Pharmacy,
Belapur, Navi Mumbai, India

Lilasrao Kadam, Bharati Vidyapeeth's College of Pharmacy

Bharati Vidyapeeth's College of Pharmacy,
Belapur, Navi Mumbai, India


1. Sánchez Martínez, M.; Blanco, A.; Castell, M. V.; Gutiérrez Misis, A.; González Montalvo, J. I.; Zunzunegui, M. V.; Otero, Á. Diabetes in Older People: Prevalence, Incidence and Its Association with Medium- and Long-Term Mortality from All Causes. Aten. Primaria2014, 46 (7), 376–384.
2. Reimann, M.; Bonifacio, E.; Solimena, M.; Schwarz, P. E. H.; Ludwig, B.; Hanefeld, M.; Bornstein, S. R. An Update on Preventive and Regenerative Therapies in Diabetes Mellitus. Pharmacol. Ther.2009, 121 (3), 317–331.
3. Sicree, R.; Shaw, J.; Zimmet, P. The Global Burden. Diabetes Impair. Glucose Toler. Bak. IDI Heart Diabetes Inst.2010.
4. Farina, E. K.; Austin, K. G.; Lieberman, H. R. Concomitant Dietary Supplement and Prescription Medication Use Is Prevalent among US Adults with Doctor-Informed Medical Conditions. J. Acad. Nutr. Diet.2014, 114 (11), 1784–1790.e2.
5. Prabhakar, P. K.; Kumar, A.; Doble, M. Combination Therapy: A New Strategy to Manage Diabetes and Its Complications. Phytomedicine2014, 21 (2), 123–130.
6. Bahmani, M.; Zargaran, A.; Rafieian-Kopaei, M.; Saki, K. Ethnobotanical Study of Medicinal Plants Used in the Management of Diabetes Mellitus in the Urmia, Northwest Iran. Asian Pac. J. Trop. Med.2014, 7, S348–S354.
7. Vogel, J. H. K.; Bolling, S. F.; Costello, R. B.; Guarneri, E. M.; Krucoff, M. W.; Longhurst, J. C.; Olshansky, B.; Pelletier, K. R.; Tracy, C. M.; Vogel, R. A.; et al. Integrating Complementary Medicine Into Cardiovascular Medicine. J. Am. Coll. Cardiol.2005, 46 (1), 184–221.
8. Šmaižien?, I.; Vaitkien?, R. Consumer Ethnocentrism and Behavior in a Market of Dietary Supplements. Procedia - Soc. Behav. Sci.2014, 156, 463–467.
9. Wagner, H. Synergy Research: Approaching a New Generation of Phytopharmaceuticals. Fitoterapia2011, 82 (1), 34–37.
10. DiPiro, J. T. Concepts in Clinical Pharmacokinetics; ASHP, 2010.
11. Mu, J.; Woods, J.; Zhou, Y.-P.; Roy, R. S.; Li, Z.; Zycband, E.; Feng, Y.; Zhu, L.; Li, C.; Howard, A. D.; et al. Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic -Cell Mass and Function in a Rodent Model of Type 2 Diabetes. Diabetes2006, 55 (6), 1695–1704.
12. Bergman, A.; Stevens, C.; Zhou, Y. Pharmacokinetic and Pharmacodynamic Properties of Multiple Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Male Volunteers. Excerpta Medica2006, 28, 55–72.
13. Jafri, S. A.; Abass, S.; Qasim, M.; others. Hypoglycemic Effect of Ginger (Zingiber Officinale) in Alloxan Induced Diabetic Rats (Rattus Norvagicus). Pak Vet J2011, 31 (2), 160–162.
14. Abdulrazaq, N. B.; Cho, M. M.; Win, N. N.; Zaman, R.; Rahman, M. T. Beneficial Effects of Ginger (Zingiber Officinale) on Carbohydrate Metabolism in Streptozotocin-Induced Diabetic Rats. Br. J. Nutr.2012, 108 (07), 1194–1201.
15. Ali, B. H.; Blunden, G.; Tanira, M. O.; Nemmar, A. Some Phytochemical, Pharmacological and Toxicological Properties of Ginger (Zingiber Officinale Roscoe): A Review of Recent Research. Food Chem. Toxicol.2008, 46 (2), 409–420.
16. Daily, J.; yang, M.; Park, S. Efficacy of Ginger for Treating Type 2 Diabetes: A Systematic Review Q1,20 and Meta-Analysis of Randomized Clinical Trials. Elsevier2015, 2015, 1–8.
17. Ismail, M. Y. M. Herb-Drug Interactions and Patient Counseling. Int J Pharm Pharm Sci2009, 1 (Suppl 1), S151–S161.
18. Beconi, M. G.; Reed, J. R.; Teffera, Y.; Xia, Y.-Q.; Kochansky, C. J.; Liu, D. Q.; Xu, S.; Elmore, C. S.; Ciccotto, S.; Hora, D. F.; et al. Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs. Drug Metab. Dispos.2007, 35 (4), 525–532.
19. Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C. L.; Ramarao, P. Combination of High-Fat Diet-Fed and Low-Dose Streptozotocin-Treated Rat: A Model for Type 2 Diabetes and Pharmacological Screening. Pharmacol. Res.2005, 52 (4), 313–320.
20. Cox, R. D. Animal Models for Diabetes: Genes, Environment and Health. Drug Discov. Today Dis. Models2013, 10 (2), e57–e58.
21. Fröde, T. S.; Medeiros, Y. S. Animal Models to Test Drugs with Potential Antidiabetic Activity. J. Ethnopharmacol.2008, 115 (2), 173–183.
22. Guo, C.; Zhang, C.; Li, L.; Wang, Z.; Xiao, W.; Yang, Z. Hypoglycemic and Hypolipidemic Effects of Oxymatrine in High-Fat Diet and Streptozotocin-Induced Diabetic Rats. Phytomedicine2014, 21 (6), 807–814.
23. Mukherjee, P. K.; Maiti, K.; Mukherjee, K.; Houghton, P. J. Leads from Indian Medicinal Plants with Hypoglycemic Potentials. J. Ethnopharmacol.2006, 106 (1), 1–28.
24. Colalto, C. Herbal Interactions on Absorption of Drugs: Mechanisms of Action and Clinical Risk Assessment. Pharmacol. Res.2010, 62 (3), 207–227.
25. Endres, C. J.; Hsiao, P.; Chung, F. S.; Unadkat, J. D. The Role of Transporters in Drug Interactions. Eur. J. Pharm. Sci.2006, 27 (5), 501–517.
26. Dhande, S.; Patil, A.; Lokegaonkar, D.; Kadam, V. Study of Pharmacodynamic Interaction of Sitagliptin, Gymnema Sylvestre, Zingiber Officinale on Experimental Rat Model. Human Journals June 25, 2015.
How to Cite
Dhande, S., Patil, A. and Kadam, L. 2015. Study of Effect of supplementation of Zingiber Officinale on pharmacokinetic profile of Sitagliptin phosphate on Streptozotocin induced type II DM Rat Model. PharmaTutor. 3, 12 (Dec. 2015), 40-45.